

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 27 April 2023 in relation to the 2022 annual report of the Group (the “**2022 Annual Report**”) and dated 29 April 2024 in relation to the 2023 annual report of the Group (the “**2023 Annual Report**”) (together the “**2022 and 2023 Annual Report**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the 2022 and 2023 Annual Report. The Company would like to provide the following supplemental information which should be read in conjunction with the 2022 and 2023 Annual Report.

The remuneration of Ms. Amy Ha, being Chief Executive Officer of the Group for the period from 3 January 2022 to 2 January 2023, for the year ended 31 December 2022 and 2023 is as follows:

	2023 <i>HK\$'000</i>	2022 <i>HK\$'000</i>
Salaries, allowances and benefits in kind	16	3,084
Pension scheme contributions	<u>—</u>	<u>18</u>
	<u>16</u>	<u>3,102</u>

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 6 November 2025

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)

Mr. Du Dong

Non-executive Directors

Mr. Chen Hui

Ms. Tian Yuze

Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping

Mr. Ha Kee Choy Eugene

Mr. To Shing Chuen